Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study found methylphenidate to be effective in treating apathy in individuals with Alzheimer disease. At a time when the recent aducanumab approval is focusing attention on the promise of disease-modifying therapies, the new findings highlight the importance of developing better symptomatic treatment options for individuals with psychiatric disorders of Alzheimer disease.
The neurological deficits caused by COVID-19, which were first reported in the early months of 2020, continue to intrigue neurologists and health-care professionals worldwide. As two new studies highlight, these manifestations are frequent and are expected to increase the burden of morbidity and mortality in the acute and chronic phases of COVID-19.
In this Review, Nassan and Videnovic discuss the alterations to the circadian system that occur in neurodegenerative disorders and highlight future directions for research in the field, including opportunities for the development of circadian-based therapeutic interventions.
In this Review, Li-Huei Tsai and colleagues discuss the ongoing work towards the generation of more physiological in vitro models of Alzheimer disease (AD), with a particular focus on the modelling of AD-related changes to the blood–brain barrier, myelination, neuroinflammation and neuronal circuits.
Despite substantial progress in the development of disease-modifying therapies for multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) remain limited. The authors present criteria for therapeutic success in PMS and consider the extent to which current drugs meet these criteria.
In this Perspective, Barnes introduces three key obstacles to progress in our understanding of racial differences in Alzheimer disease and highlights evidence-informed strategies that can move the field forward.